Paul Andrew Moore
Chief Scientific Officer · Zymeworks Inc.
- 2026
- Jan 13, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Paul Andrew Moore files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kenneth Galbraith - $3.34M in ZYME purchases and sales in the last 12 months
- Jeffrey T. L. Smith - $476K in ZYME purchases and sales in the last 12 months
- Adam Schayowitz - $358K in ZYME purchases and sales in the last 12 months
- Mark Hollywood - $139K in ZYME purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Paul Andrew Moore?
Paul Andrew Moore is a corporate insider, tracked as Chief Scientific Officer of Zymeworks Inc. (ZYME). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Paul Andrew Moore last file a Form 4?
The most recent primary Form 4 on record is dated 13 January 2026, one of 2 filings going back to 2026.
Has Paul Andrew Moore been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($721K) across all tracked filings.
